Showing 1541-1550 of 1732 results for "".
- Neurologic Recovery After Severe COVID-19 Leaves One-Third With Worsening Cognitive Symptoms at 12 Monthshttps://practicalneurology.com/news/neurologic-recovery-after-severe-covid-19-leaves-one-third-with-worsening-symptoms-at-12-months/2469977/Among individuals who were admitted to the intensive care unit with COVID-19, outcomes were worse for those who had neurologic symptoms both in hospital and over 12 months after COVID-19 diagnosis, including cognitive deficits in 41%, regardless of whether they had neurologic symptoms while in th
- One-Time Gene Therapy Delivered Neurosurgically Delivered to Striatum Provided Sustained Motor Function Improvements in Parkinson Diseasehttps://practicalneurology.com/news/one-time-gene-therapy-delivered-neurosurgically-delivered-to-striatum-provided-sustained-motor-function-improvements-in-parkinson-disease/2469381/
- New Formulation of Dihydroergotamine for Acute Migraine Treatment Submitted to FDA for Approvalhttps://practicalneurology.com/news/new-drug-application-for-dihydroergotamine-mesylate-acute-migraine-treatment-submitted-to-fda/2469425/In the phase 3 open-label STOP 301 study (NCT03557333), participants with migraine who treated attacks with dihydroergotamine mesylate (DHE) (inp104; Impel Neuropharma, Seattle, CA) had pain relief (66.3%), pain freedom (38%), and free
- Evidence Shows Telemedicine With Neurologists Is Effective For Patients and Caregivershttps://practicalneurology.com/news/evidence-shows-telemedicine-with-neurologists-is-effective-for-patients-and-caregivers/2469091/According to a review of the evidence conducted by the American Academy of Neurology (AAN) and published in the journal Neurology, seeing a neurologist by video may be as effective as an in-person visit.
- Clinical Trial of Nanocrystalline Gold for Amyotrophic Lateral Sclerosis Completes Double-Blinded Phasehttps://practicalneurology.com/news/clinical-trial-of-nanocrystalline-gold-for-amyotrophic-lateral-sclerosis-completes-double-blinded-phase/2469688/All patient visits have been completed in the phase 2 study (NCT04098406) of catalytically active gold nanocrystals (Clene Nanomedicine, Salt Lake City, UT) for early-stage amyotrophic lateral scl
- Combination Laser Therapy and Keytruda Significantly Increases Survival for Those with rHGAhttps://practicalneurology.com/news/combination-laser-therapy-and-keytruda-significantly-increases-survival-for-those-with-rhga/2486025/Key Takeaways Laser interstitial thermal therapy (LITT) + Keytruda significantly improved median overall survival, progression-free survival, and 18-month survival compared with non-LITT surgery + Keytruda for people with recurrent high-grade astrocytoma.
- CNM-Au8 Did Not Slow ALS Progression in HEALEY ALS Platform Trialhttps://practicalneurology.com/news/cnm-au8-did-not-slow-als-progression-in-healey-als-platform-trial/2485956/Key Takeaways CNM-Au8 did not slow ALS disease progression compared with placebo over 24 weeks in the HEALEY ALS Platform Trial. Secondary outcomes—Combined Assessment of Function and Survival score, slow vital capacity decline, and survival free of p
- Wrist-Worn Neurostimulation Device for Hand Movement Rehabilitation after Stroke or Spinal Injury Receives FDA Clearancehttps://practicalneurology.com/news/wrist-worn-neurostimulation-device-for-hand-movement-rehabilitation-after-stroke-or-spinal-injury-receives-fda-clearance/2473788/The Food and Drug Administration (FDA) has granted 510(K) clearance to NeuStim (Neuvotion, Stamford, CT), a noninvasive, surgery-free wearable neurostimulation device used to aid in hand movement recovery in patients who have experienced a stroke or spinal cord injury (SCI). The device can scan m
- A New Embolic Material Stops the Flow of Blood to Brain Tumorshttps://practicalneurology.com/news/a-new-embolic-material-stops-the-flow-of-blood-to-brain-tumors/2470534/NeoCast (Arsenal Medical, Waltham, MA), a solvent-free, nonadhesive liquid embolic material designed to stop blood flow to brain tumors, was shown to be feasible in providing complete occlusion of targeted vessels. The material was also shown to achieve safety endpoints. Results of the EMBO-01 cl
- XBiotech Launches Study of Hutrukin Therapy for Injury Reduction After Ischemic Stroke Reperfusionhttps://practicalneurology.com/news/xbiotech-launches-study-of-hutrukin-therapy-for-injury-reduction-after-ischemic-stroke-reperfusion/2470179/XBiotech Inc. (Austin, TX) announced it has enrolled the first patient in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate the safety and pharmacokinetics of Hutrukin Therapy, a human derived, modification-free antibody. The company is developing Hutrukin as